The initial public offering of Gaudium IVF and Women’s Health Ltd opened on Friday, February 20, marking the company’s entry into the Indian stock market. The New Delhi-based healthcare services provider, which specialises in fertility treatments and women’s health services, has fixed its price band at Rs 75 to Rs 79 per equity share for the IPO. The issue aims to raise Rs 165 crore from public investors.
The subscription period for the IPO commenced on February 20 and will remain open until February 24. Investors are expected to include retail individual investors, high net worth individuals (HNIs), and institutional participants. On the first day of the IPO, the grey market premium (GMP) was reported at Rs 8.5, indicating a potential listing gain of approximately 10.76 % over the upper end of the issue price band. A positive GMP often reflects strong demand in the unlisted market for an IPO subscription.
Gaudium IVF and Women’s Health Ltd operates a network of fertility clinics and healthcare facilities offering a range of services including in vitro fertilisation (IVF), infertility treatments, gynaecological care, and related diagnostic services. The company has grown its footprint across multiple cities in India, targeting a rising demand for specialised women’s health and reproductive services.
The capital raised through the IPO will be used to fund expansion initiatives. A significant portion of the proceeds is earmarked for setting up new fertility and women’s health centres in key urban and semi-urban locations. This expansion is expected to enhance accessibility for patients seeking reproductive and women’s healthcare services across regions. In addition, the funds will be allocated to strengthen the company’s diagnostic capabilities and invest in advanced medical equipment. General corporate purposes will also be supported by the net proceeds of the issue.
Market analysts are monitoring subscription patterns, given the increasing investor interest in healthcare IPOs. Healthcare services providers, particularly those focused on specialised segments like fertility and women’s wellness, have drawn attention due to secular demand growth, rising healthcare spending, and improving insurance coverage. Investors often view such companies as beneficiaries of long-term demographic trends and growing awareness of reproductive health.
As the IPO subscription progresses, the company and its book running lead managers will track bids received from different investor categories. Following the close of the subscription window on February 24, the allotment process will begin, with finalisation expected within a few days. The company will then announce its proposed listing date on stock exchanges, where its equity shares are expected to debut.
Potential investors are advised to review the offer document, understand the risks associated with investing in IPOs, and consider their investment objectives before participating. While early indications such as the grey market premium suggest positive sentiment, overall subscription levels and market conditions will play a key role in determining the IPO’s success.
In conclusion, the opening of the Gaudium IVF and Women’s Health Ltd IPO represents an important development in the healthcare services segment of India’s capital markets. With its focus on fertility and women’s health, the company aims to leverage growing demand while offering an investment opportunity to a broad set of investors.
